Non-Invasive Auricular Vagus Nerve Stimulator: New Science-Based Guide Released

Oct 14, 2026

Nuropod by Parasym has released a science-based guide on its non-invasive auricular vagus nerve stimulation device, covering the AVNT waveform, its research record, and adjustable settings designed to support the nervous system.

Sacramento, United States, October 14, 2026 /PressCable/ -- Nuropod by Parasym, a wearable neurotechnology brand, has published a science-based guide detailing the research behind its non-invasive auricular vagus nerve stimulation device and the proprietary AVNT™ waveform it uses.

More information is available at https://nuropod.com/pages/science-behind-nuropod

The guide comes as interest in non-invasive vagus nerve stimulation as an at-home option continues to grow, and as wearable neurotechnology moves from research settings into everyday routines. Nuropod's guide explains how the company's device fits that shift, from where it sits on the ear to the research supporting its technology.

The guide begins by explaining how the device works, delivering AVNT through an earpiece that clips onto the tragus, the part of the outer ear just in front of the ear canal, where the vagus nerve reaches the skin. It also traces how vagus nerve stimulation, once limited to surgical implants, became available through non-invasive methods, and notes that AVNT was developed over more than a decade of research.

The guide then outlines the research record behind the device. Research using Parasym's AVNT technology spans 60+ completed clinical studies, with 100+ ongoing, and has been conducted with institutions including Harvard and UCLA.

Measurable outcomes covered in the guide include markers of inflammation and heart function. In clinical studies, IL-6 fell by an average of 78% and TNF alpha by an average of 23%, while heart muscle function improved by an average of 29%.

Practical use rounds out the guide's focus. The device offers 45 adjustable energy levels, letting users tailor settings rather than rely on a single fixed level, and requires no gel, surgery, or prescription. Most people use it for around 30 minutes, once or twice a day, while working, reading, or watching television.

Readers interested in the full research background can explore the complete guide and the device at https://nuropod.com/.

Disclaimer: Research referenced in this article was conducted using Parasym's neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/

Source: PressCable

Release ID: 89206182

Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.